Synthetic miR-145 Mimic Enhances the Cytotoxic Effect of the Antiangiogenic Drug Sunitinib in Glioblastoma

Cell Biochemistry and Biophysics

Volumn 72, Issue 2, 2015, Pages 551-557

  Liu, Hongwei ^a   Liu, Zhixiong ^a   Jiang, Bing ^a   Huo, Lei ^a   Liu, Jinfang ^a   Lu, Jingchen ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

GBM; Mir 145 mimic; Suntinib

Indexed keywords

ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; MICRORNA; MIRN145 MICRORNA, HUMAN; PYRROLE DERIVATIVE; SUNITINIB;

APOPTOSIS; CELL LINE; DRUG EFFECTS; GENETICS; GLIOBLASTOMA; HUMAN; METABOLISM;

ANGIOGENESIS INHIBITORS; APOPTOSIS; CELL LINE; GLIOBLASTOMA; HUMANS; INDOLES; MICRORNAS; PYRROLES;

EID: 84930872171     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-014-0501-8     Document Type: Article

References (40)

1. Furnari, F. B., et al. (2007). Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes & Development,21(21), 2683–2710.
2. Noda, S. E., et al. (2009). Molecular advances of brain tumors in radiation oncology. Semininars in Radiation Oncology,19(3), 171–178.
3. Desjardins, A., et al. (2005). Chemotherapy and novel therapeutic approaches in malignant glioma. Front Biosci,10, 2645–2668.
4. Tuettenberg, J., Friedel, C., & Vajkoczy, P. (2006). Angiogenesis in malignant glioma—a target for antitumor therapy? Critical Reviews in Oncology Hematology,59(3), 181–193.
5. Cohen, M. H., et al. (2009). FDA drug approval summary: Bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist,14(11), 1131–1138.
6. di Tomaso, E., et al. (2011). Glioblastoma recurrence after cediranib therapy in patients: Lack of “rebound” revascularization as mode of escape. Cancer Research,71(1), 19–28.
7. Wick, W., et al. (2011). Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncology,13(6), 566–579.
8. Bartel, D. P. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell,116(2), 281–297.
9. Alvarez-Garcia, I., & Miska, E. A. (2005). MicroRNA functions in animal development and human disease. Development,132(21), 4653–4662.
10. Zhang, B., et al. (2007). microRNAs as oncogenes and tumor suppressors. Development Biology,302(1), 1–12.
11. Lawler, S., & Chiocca, E. A. (2009). Emerging functions of microRNAs in glioblastoma. Journal of Neuro-oncology,92(3), 297–306.
12. Li, Y., et al. (2009). MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Research,69(19), 7569–7576.
13. Godlewski, J., et al. (2008). Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Research,68(22), 9125–9130.
14. Kim, T. M., et al. (2011). A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Research,71(9), 3387–3399.
15. Lee, H. K., et al. (2013). MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor. PLoS ONE,8(2), e54652.
16. Rani, S. B., et al. (2013). MiR-145 functions as a tumor-suppressive RNA by targeting Sox9 and adducin 3 in human glioma cells. Neuro Oncology,15(10), 1302–1316.
17. La Rocca, G., et al. (2009). Growth inhibition by microRNAs that target the insulin receptor substrate-1. Cell Cycle,8(14), 2255–2259.
18. Sachdeva, M., & Mo, Y. Y. (2010). miR-145-mediated suppression of cell growth, invasion and metastasis. American Journal of Translational Research,2(2), 170–180.
19. Speranza, M. C., et al. (2012). NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget,3(7), 723–734.
20. Lu, Y., et al. (2013). MiR-145 reduces ADAM17 expression and inhibits in vitro migration and invasion of glioma cells. Oncology Reports,29(1), 67–72.
21. Wan, X., et al. (2014). ROCK1, a novel target of miR-145, promotes glioma cell invasion. Molecular Medicine Reports,9(5), 1877–1882.
22. Lee, H. K., et al. (2013). Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget,4(2), 346–361.
23. Shi, L., et al. (2014). miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2. Neuromolecular Medicine,16(2), 517–528.
24. Xu, N., et al. (2009). MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell,137(4), 647–658.
25. Carthew, R. W. (2006). Gene regulation by microRNAs. Current Opinion in Genetics & Development,16(2), 203–208.
26. Lovat, F., Valeri, N., & Croce, C. M. (2011). MicroRNAs in the pathogenesis of cancer. Seminars in Oncology,38(6), 724–733.
27. Quintavalle, C., et al. (2012). miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPmu. Oncogene,31(7), 858–868.
28. Fang, L., et al. (2011). MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-beta8. Oncogene,30(7), 806–821.
29. Sasayama, T., et al. (2009). MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. International Journal of Cancer,125(6), 1407–1413.
30. Kefas, B., et al. (2010). Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro Oncol,12(11), 1102–1112.
31. Guha, A., et al. (1995). Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. International Journal of Cancer,60(2), 168–173.
32. Wang, D., et al. (1999). Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Research,59(7), 1464–1472.
33. Lokker, N. A., et al. (2002). Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: Evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Research,62(13), 3729–3735.
34. Westermark, B., Heldin, C. H., & Nister, M. (1995). Platelet-derived growth factor in human glioma. Glia,15(3), 257–263.
35. de Bouard, S., et al. (2007). Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol,9(4), 412–423.
36. Chahal, M., et al. (2010). MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro Oncology,12(8), 822–833.
37. Strawn, L. M., et al. (2000). Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts. Clinical Cancer Research,6(7), 2931–2940.
38. Zhou, Q., Guo, P., & Gallo, J. M. (2008). Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clinical Cancer Research,14(5), 1540–1549.
39. Gore, M. E., et al. (2011). Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer,117(3), 501–509.
40. Oberoi, R. K., Mittapalli, R. K., & Elmquist, W. F. (2013). Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain. Journal of Pharmacology and Experimental Therapeutics,347(3), 755–764.